# A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)

> **NCT04129996** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 46 (estimated)

## Conditions studied

- Triple-Negative Breast Cancer

## Interventions

- **DRUG:** camrelizumab in combination with nab-paclitaxel and famitinib

## Key facts

- **NCT ID:** NCT04129996
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-10-01
- **Primary completion:** 2022-09-01
- **Final completion:** 2022-09-01
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2022-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04129996

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04129996, "A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)". Retrieved via AI Analytics 2026-08-20 from https://api.ai-analytics.org/clinical/NCT04129996. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*